The Innovative Medicines Initiative is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.
PROactive
The PROactive project aims to develop validation and use of patient reported outcome (PRO) tools to investigate dimensions of physical activity that are judged as being essential by patients living with COPD. A better understanding of all relevant dimensions (symptoms, distress, etc.) of physical activity that are meaningful to COPD patients will help describe the patients' experience of COPD. PROactive will be developed with input from the regulatory authorities, such as the European Medicines Agency (EMA). Once appropriately validated, PROactive will be used to evaluate the benefit of new treatments such as new medicinal products for COPD patients.
|
|
U-BIOPRED
U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) is a research project to understand more about severe asthma that involves scientists from universities, research institutes, the pharmaceutical industry and small companies.
|
|
